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Beckett Street, Leeds LS9 7TF, UKAs a clinical setting in which local live biological therapy is
already well established, non-muscle invasive bladder cancer
(NMIBC) presents intriguing opportunities for oncolytic viro-
therapy. Coxsackievirus A21 (CVA21) is a novel intercellular
adhesion molecule-1 (ICAM-1)-targeted immunotherapeutic
virus. This study investigated CVA21-induced cytotoxicity in
a panel of human bladder cancer cell lines, revealing a range
of sensitivities largely correlating with expression of the viral
receptor ICAM-1. CVA21 in combination with low doses of
mitomycin-C enhanced CVA21 viral replication and oncolysis
by increasing surface expression levels of ICAM-1. This was
further conﬁrmed using 300-mm precision slices of NMIBC
where levels of virus protein expression and induction of
apoptosis were enhanced with prior exposure to mitomycin-C.
Given the importance of the immunogenicity of dying cancer
cells for triggering tumor-speciﬁc responses and long-term
therapeutic success, the ability of CVA21 to induce immuno-
genic cell death was investigated. CVA21 induced immuno-
genic apoptosis in bladder cancer cell lines, as evidenced by
expression of the immunogenic cell death (ICD) determinant
calreticulin, and HMGB-1 release and the ability to reject
MB49 tumors in syngeneic mice after vaccination with MB49
cells undergoing CVA21 induced ICD. Such CVA21 immuno-
therapy could offer a potentially less toxic, more effective
option for the treatment of bladder cancer.Received 5 February 2018; accepted 6 February 2018;
https://doi.org/10.1016/j.omto.2018.02.001.
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Urothelial cancer of the bladder is the seventhmost common cancer in
the UK, with over 10,000 new cases annually in the UK.1 Superﬁcial,
non-muscle invasive bladder cancers (NMIBCs) are managed with
cystoscopic transurethral resection of all visible lesions followed by
intravesical chemotherapy and/or immunotherapy.2 The use of Bacil-
lus Calmette-Guerin (BCG) as an immunotherapy for NMIBC and its
proven effects of reducing recurrence and progression and improving
disease-speciﬁc survival revolutionized the treatment of this malig-
nancy in the 1970s. However, the potential for serious side effects of
local and systemic BCG infection as well as the fact that there is a sig-
niﬁcant (30%) group of non-responder patients to BCG highlights theMol
This is an open access article under the CC BY-Nneed to develop future immune-based therapies that overcome these
problems.3 The precisemechanisms underpinning the clinical efﬁcacy
of BCG remain unclear. Urothelial cells (including bladder cancer cells
themselves) and various components of the immune system both have
crucial roles. The possible involvement of bladder cancer cells includes
attachment and internalization of BCG, secretion of cytokines and
chemokines, and presentation of BCG and/or cancer cell antigens to
cells of the immune system. Immune cell subsets that have potential
roles in BCG therapy include CD4+ and CD8+ lymphocytes, natural
killer cells, granulocytes, macrophages, and dendritic cells. Bladder
cancer cells are killed through direct cytotoxicity by these cells; by
secretion of soluble factors, such as TRAIL (tumor-necrosis-factor-
related apoptosis-inducing ligand); and, to some degree, by the direct
action of BCG. New agents are vital, capable of the immunothera-
peutic effects of BCG but without the toxicity and need to use a poten-
tially hazardous live agent in the clinic. The accessibility and superﬁ-
cial location of NMIBC allows direct intravesical administration of
antitumor agents and is an ideal model for evaluation of new therapies
as, through insertion of a conventional urinary catheter, precise
modulation of infusion volume, infusion rate, time of retention in
the bladder by catheter clamping, as well as frequency of treatments
can be precisely undertaken as well as combination with other agents.
Alternatives to BCG have been long sought, due to its toxicity and
limited efﬁcacy and, also in recent years, the difﬁculty with its manu-
facture.4,5 Viruses, both non-replication for gene transfer and replica-
tion-competent oncolytic viruses (OVs), have been evaluated for the
treatment of NMIBC. These viruses infect and selectively lyse tumor
cells, leaving non-transformed cells unharmed.6,7
The roles of the host immune system in contributing to the therapeu-
tic activity of OV through intratumoral and systemic delivery are nowecular Therapy: Oncolytics Vol. 9 June 2018 ª 2018 The Authors. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapy: Oncolyticswell recognized.8–10 Emerging evidence has shown that oncolytic
virotherapy induces immunogenic cell death (ICD).11–13 This is char-
acterized by expression of potent danger signals, such as alterations in
the composition of the plasma membrane of dying cells (including
surface-exposed calreticulin [ecto-CRT] and heat shock proteins),
as well as release of ATP and high-mobility group box 1 protein
(HMGB-1). These are thought to be the optimal way to trigger acti-
vation of the immune system against cancer, ultimately resulting in
long-term success of virotherapy.14 Coxsackievirus A21 (CVA21), a
naturally occurring “common cold” intercellular adhesion mole-
cule-1 (ICAM-1)-targeted RNA virus, has exhibited selective onco-
lytic activity in a range of solid tumors.15–19 CAVATAK is a novel
bio-selected formulation of CVA21, whose oncolytic and immuno-
therapeutic capacity has already been clearly demonstrated in
in vitro cultures, in vivo melanoma models, and several human trials
where CAVATAK has been administered intratumorally alone or in
combination with immune checkpoint inhibitors, resulting in signif-
icant bystander effects with reduction of distant non-injected
metastases.20
We evaluated CVA21 as a novel oncolytic virus for the treatment of
human bladder cancer. Bladder cancer cell lines were assessed for sur-
face expression of the viral receptors ICAM-1 and decay accelerating
factor (DAF) by ﬂow cytometry and subsequent susceptibility to
viral-induced lytic infection. We hypothesized that lytic infection
could be facilitated/enhanced by treatment of bladder cancer cell lines
with Mitomycin-C by increasing ICAM-1 expression on the surface
of the bladder cancer cells. Furthermore, we investigated the mode
of cell death induced by CVA21 and potential immunogenicity in
an immunocompetent murine bladder cancer model.
RESULTS
Susceptibility of Bladder Cancer Cell Lines to CVA21 Infection
Monolayers of each of the ten bladder cancer cell lines were inocu-
lated with CVA21 at MOIs from 0 to 50 and cell viability quantiﬁed
72 hr post-infection using the 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTS) colorimetric cell-viability assay.
As shown in Figure 1A, cell viability was signiﬁcantly decreased in
the 253J, VM-UB2, HCV29, T24, TCCSUP, and 5637 cell lines
compared to J82, KU19-19, VMCUB1, and RT-112 at MOIsR 1.0.
Heat-inactivated CVA21 did not affect the cell viability over the range
of MOIs tested, demonstrating that live CVA21 was required for on-
colytic potency (Figure S1A).
To conﬁrm whether or not CVA21 was entering the least susceptible
bladder cancer cell lines, the distribution of CVA21 was examined
24 hr post-infection in the bladder cancer cell lines using immunoﬂu-
orescence and confocal microscopy. The six most susceptible bladder
cancer cell lines, 253J, VM-CUB2, HCV29, T24, 5637, and TCCSUP,
all showed CVA21 distributed in the cytoplasm, often with a peri-nu-
clear localization. Despite the apparent lack of susceptibility to the
virus, J82 and KU19-19 cell lines also demonstrated clear infectivity
by CVA21 in contrast to VMCUB and RT-112 that remained refrac-
tile to infection (Figure 1A).2 Molecular Therapy: Oncolytics Vol. 9 June 2018Expression of ICAM-1 and DAF on Bladder Cancer Cell Lines
To determinewhether the infectivity of the bladder cancer cell lines was
due to their viral receptor expression proﬁles, the surface expression of
ICAM-1 and DAF was examined by ﬂow cytometric analysis. Whereas
all cancer cell lines expressed a high level of DAF, only themost suscep-
tible cell lines, 253J, VM-CUB2, HCV29, T24, TCCSUP, and 5637, also
expressed a high level of ICAM-1, with the exception of J82, which
despite expressing ICAM-1 to similar levels still didnot succumb toviral
infection (Figure 1B). Of note, J82 was the only cell line that showed a
signiﬁcant increase in the antiviral cytokine, interferon (IFN) b, post-
CVA21 treatment (Figure S2). A lower level of ICAM-1 was observed
on the KU19-19 and VMCUB1 cell lines and minimal to no surface
ICAM-1on theRT-112 cells (Figure1B).Quantiﬁcationof themeanab-
solute number of membrane-bound ICAM-1 molecules per cell using
QuantiBRITEPEcalibrationbeads further conﬁrmed this differing viral
receptor expression proﬁle for the bladder cancer cell lines (Figure 1C).
These results indicated that a threshold of at least 5,000 ICAM-1 mol-
ecules per cell was required in order for the virus to exhibit activity.
To further demonstrate the importance of ICAM-1 expression for
viral infectivity, the KU19-19 cell line that had been shown to display
a small subset of ICAM-1-positive cells was sorted into ICAM-1-pos-
itive and negative subsets and the susceptibility of these sorted popu-
lations to virus assessed as before 72 hr post-infection using the MTS
colorimetric cell-viability assay. As shown in Figure 1D, the ICAM-1-
negative population showed no susceptibility to the virus, whereas the
ICAM-1-positive cells showed enhanced susceptibility compared to
the negative population and whole unsorted KU19-19 cells.
It has been reported that oncogenic Kras mutations in pancreatic
acinar cells induce the expression of ICAM-1.21 However, in the
bladder cancer cell lines we studied, the Sanger COSMIC database22
showed no common genomic mutations in one or more of a set of
genes (PIK3CA, RB1, RAS, TSC1, CDKN2A, PTEN, and TP53) asso-
ciated with ICAM-1 expression or the susceptibility of particular
bladder cancer cell lines to CVA21 infection.
In Vitro Survival of Cells following Treatment with a Combination
of CVA21 and Chemotherapy
Unpublished work from our group had shown that radiation upregu-
lates expression of the ICAM-1 cell surface receptor on bladder cancer
cell lines. However, as radiation is not normally used as a treatment for
NMIBC, the commonly used chemotherapy, Mitomycin C, was tested
on six bladder cancer cell lines to determine any effects on ICAM-1 re-
ceptor expression. Bladder cancer cell lines T24, TCCSUP, and 5637
were treated with increasing doses of Mitomycin-C (0.05–4 mg/mL)
for an hour and themeanﬂuorescence intensity of ICAM-1 expression
determined byﬂow cytometry after incubation in growthmedia for 24,
48, and 72 hr. Cytotoxic effects of Mitomycin-C were assessed using
the live/dead cell discriminator, ViViD. Figure 2A shows that, at low
doses of Mitomycin-C (up to 0.5 mg/mL), ICAM-1 surface expression
increased in all three cell lines without any signiﬁcant cytotoxic effects.
This increase in Mitomycin-C-induced ICAM-1 expression was
further conﬁrmed at the RNA level in the 5637 cell line. RNA was
Figure 1. Susceptibility of Bladder Cancer Cell Lines to
CVA21 Infection and Expression Profile of Surface ICAM-1
and DAF on Bladder Cancer Cell Lines
(A) Monolayer cultures of human bladder cancer cells were
challenged with increasing multiplicities of CVA21 and assessed
for cell survival at 72 hr post-infection, with live cells being
quantified by MTS assay. Confocal images of human bladder
cancer cell lines 24 hr post-CVA21 infection are shown (green,
CVA21 viral proteins; red, wheat germ agglutinin; blue, nuclei
stained with TO-PRO-3). Magnification 40 is shown. (B) Surface
expression of ICAM-1 and DAF on bladder cancer cell lines was
determined by flow cytometry. Cell lines were incubated with the
relevant PE-conjugated isotype control antibody (black histo-
gram), anti-DAF monoclonal antibody, or anti-ICAM-1 mono-
clonal antibody (gray histogram). (C) Absolute numbers of ICAM-1
molecules on bladder cancer cells were determined by Quanti-
BRITE PE analysis. (D) KU19-19 bladder cancer cells were
stained with an anti-ICAM-1-PE antibody and sorted into ICAM-1-
positive or negative populations using magnetic enrichment of
PE-positive cells. Together with the whole unsorted KU19-19
population, the different fractions were challenged with increasing
multiplicities of CVA21 and assessed for cell survival at 72 hr post-
infection, with live cells being quantified by MTS assay.
www.moleculartherapy.org
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Figure 2. The Effects of Mitomycin-C on Bladder
Cancer Cells and Viral Replication
(A) Low doses of Mitomycin-C upregulate ICAM-1 protein
expression with minimal cytotoxic effects. Bladder cancer
cell lines were either left untreated or treated with Mito-
mycin-C at increasing doses for one hour before deter-
mining the mean fluorescence intensity (MFI) of ICAM-1
expression by flow cytometry after 24, 48, and 72 hr. The
cells were also assessed for any cytotoxicity using the
live/dead cell discriminator, ViViD. Data represent aver-
aged results from two independent experiments, and
two-way ANOVA statistical analysis was performed.
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. (B)
Effect of Mitomycin-C on CVA21 replication in bladder
cancer cell lines is shown. Bladder cancer cell lines were
treated with or without 0.5 mg/mL Mitomycin-C for 1 hr
before infecting with CVA21 at MOI of 11.44 for T24, 1.0
for TCCSUP, 1.8 for 5637, and 25 for RT112. Superna-
tants were harvested 24, 48, and 72 hr after infection, and
viral titers were measured by standard plaque assays on
SKMEL-28 cell monolayers. Graphs represent pooled
data from two independent experiments. *p < 0.05.
Molecular Therapy: Oncolyticsextracted from the 5637 cell line, which had been treated with doses of
Mitomycin-C up to 0.8 mg/mL, and qPCR performed. Figure S3 shows
upregulated expression of ICAM-1 along with another viral receptor
DAF in the 5637 cell line in response to increasing doses of Mito-
mycin-C treatment.
To investigate whether the increased ICAM-1 viral receptor expres-
sion induced by Mitomycin-C treatment of bladder cancer cells facil-4 Molecular Therapy: Oncolytics Vol. 9 June 2018itates CVA21 entry and thus enhanced viral
replication, viral titers were measured by stan-
dard plaque assays on SKMEL-28 cell mono-
layers. Three susceptible bladder cancer cell
lines (T24, TCCSUP, and 5637) and as a control
one refractile cell line (RT-112) were treated
with or without 0.5 mg/mL Mitomycin-C for
1 hr before infecting with CVA21 for 5 hr and
incubation in growth media for 24, 48, and
72 hr post-infection. Cell supernatant was
collected for extracellular virus quantiﬁcation.
The results showed that, in the T24 and
TCCSUP cells, there were increased virus yields
by 72 hr in the combination-treated cells
compared to virus alone. This was true for the
5637 cell line up to 48 hr but then virus yield
fell by 72 hr, probably due to signiﬁcant cell
death in this culture. RT-112, which had been
shown to be refractile to infection, showed no
change in virus yield with either treatment con-
dition (Figure 2B). Similarly, Mitomycin-C
treatment of the ICAM-1-negative sorted cells
from the cell line KU19-19 also did not induce
ICAM-1 expression on these cells, and they re-mained insensitive to the virus (data not shown). These results sug-
gest that, in ICAM-1-expressing bladder cancer cells, Mitomycin-C
treatment can increase further the ICAM-1 surface expression, thus
facilitating enhanced CVA21 uptake and subsequent replication.
Induction of Death by CVA21 in Bladder Cancer Cells
To characterize the cell death pathways involved, the presence of
apoptosis markers after treatment with Mitomycin-C, CVA21, or
Figure 3. CVA21-Induced Cell Death of Bladder
Cancer Cell Lines
(A) Determination of levels of apoptosis in three bladder
cancer cell lines left untreated or treated with Mitomy-
cin-C, CVA21, or the combination at 24, 48, and 72 hr
post-treatment by means of annexin-V- and 7AAD-based
flow cytometry. Graphs represent pooled data from two
independent experiments, and the statistical significance
of the treatment group comparisons was analyzed using
two-way ANOVA; *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001. (B) Representative dot plots recorded for
TCCSUP cells following the different treatments at 24, 48,
and 72 hr post-treatment are shown. (C) Apoptosis
(quantified via caspase 3/7 activity) in three bladder can-
cer cell lines left untreated or treated with Mitomycin-C,
CVA21, or the combination at 48 and 72 hr post-treat-
ment is shown. Graphs represent pooled data from two
independent experiments, and the statistical significance
of the treatment group comparisons was analyzed using
two-way ANOVA; *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001. (D) Increase in percentage cell survival was
seen in CVA21 and combination-treated cells with Z-VAD-
FMK, apoptosis inhibitor, whereas the necroptosis inhib-
itor, necrostatin-1, failed to increase cell survival in bladder
cancer cell lines treated with CVA21 alone or in combi-
nation with Mitomycin-C. Graphs represent pooled data
from two independent experiments, and the statistical
significance of the treatment group comparisons was
analyzed using two-way ANOVA; *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001. (E) Western blot analysis
demonstrating absence of RIP1 and RIP3 necroptosis
markers but upregulation of cleaved PARP in TCCSUP
cells 72 hr post-CVA21 infection is shown.
www.moleculartherapy.orgthe combination were assessed. Annexin V-7AAD-based ﬂuores-
cence-activated cell sorting (FACS) analyses showed signiﬁcant upre-
gulation of annexin V staining at 48 hr and 72 hr after CVA21 infec-
tion in all three bladder cancer cell lines tested. This induction of cellMoldeath was enhanced when cells had been pre-
treated with Mitomycin-C (0.5 mg/mL). In
contrast, Mitomycin-C treatment alone showed
no signiﬁcant cytotoxicity over the untreated
control cells (Figures 3A and 3B). Further
conﬁrmation of this apoptotic cell death
pathway induced by CVA21 was demonstrated
by the activation of the effector caspases, cas-
pase-3 and -7, 48 hr after infection (Figure 3C).
Furthermore, pre-treatment with the pan-cas-
pase chemical inhibitor zVAD rescued the cells
from virus-induced death whereas necrostatin-1
had no effect (Figure 3D). To exclude the
involvement of additional interconnected death
pathways, western blotting of whole-cell lysates,
untreated, Mitomycin-C treated, or CVA21
treated with or without Mitomycin-C, were
analyzed using a PARP antibody (apoptosismarker) as well as RIP1 and RIP3 antibodies (necroptosis). The pro-
tein levels of RIP1 and RIP3 either decreased or did not change in any
of the bladder cancer cell lines exposed to CVA21 and combination
treatment whereas, in contrast, the whole PARP was cleaved, yieldingecular Therapy: Oncolytics Vol. 9 June 2018 5
Figure 4. EnhancedCytotoxicity ofMitomycin-C and
CVA21 on Bladder Cancer Tumor Slices
Precision-cut slicing of resection material from a patient
with squamous bladder cancer was performed using a
vibratome. The 300-mm slices were either left untreated or
treated with Mitomycin-C, CVA21, or the combination and
then cultured for 48 hr. Slices were then fixed, paraffin
embedded, and 4-mm sections prepared. These sections
together with a section from the original biopsy were
stained for (A) presence of viral protein (red) and the nu-
clear stain TO-PRO-3 (blue) and (B) evidence of apoptosis
using the TumorTACS in situ apoptosis detection kit
(apoptotic cells are identified by the dark brown staining).
Magnification 40 is shown.
Molecular Therapy: Oncolyticsan 89-kD PARP fragment (Figure 3E). Altogether, these data indi-
cated that the main mechanism for CVA21-induced cell death in
bladder cancer cells was induction of apoptosis.
Enhanced Cytotoxicity of Mitomycin-C and CVA21 on Bladder
Cancer Slices
To test the combination treatment of CVA21 and Mitomycin-C in a
preclinical model system that represents both tumor architecture,
heterogeneity, and the complexity of a tumor in situ, we took advan-
tage of a fresh bladder tumor specimen that came into our lab from
which 300-mm precision-cut slices of tumor were prepared. Slices
with or without pre-treatment with Mitomycin-C (0.5 mg/mL) for
1 hr were infected with CVA21 (5  106 plaque-forming units
[PFU]/mL) and cultured for 48 hr. Control slices of the same tumor,6 Molecular Therapy: Oncolytics Vol. 9 June 2018which had not been exposed to any treatment
but cultured for the same period, were ﬁxed
simultaneously and embedded in parafﬁn for
histological analysis. Immunoﬂuorescent stain-
ing for the presence of viral protein showed
increased viral replication within the combina-
tion-treated slices as compared to the CVA21-
alone-treated tumor slice (Figure 4A). As ex-
pected, there was no evidence of virus within
the Mitomycin-C-treated or untreated slices.
Furthermore, a signiﬁcantly higher level of
apoptotic activity within the combination-
treated tissue slice as compared to CVA21- or
Mitomycin-C-alone-treated slices was observed.
The control slice had little to no evidence of
apoptotic cells, reﬂecting the situation in the
original tumor biopsy (Figure 4B).
Immunogenicity of Cell Death Induced by
CVA21
In order to determine the immunogenic proﬁle of
CVA21-infected bladder cancer cell lines, 3 sus-
ceptible cell lines (T24, 5637, and TCCSUP)
were infected with CVA21 at an MOI of 11.44
for T24, 1.0 for TCCSUP, and 1.8 for 5637 andanalyzed for expression of the ICD determinants calreticulin, HSP70,
extracellular ATP, and high-mobility group box 1 (HMGB1) at 24,
48, and 72 hr. This treatment induced surface expression of ecto-calre-
ticulin on two out of the three cell lines (T24 and 5637), which was
particularly marked by 72 hr in the combination-treated cells (Fig-
ure 5A). No signiﬁcant changes in surface expression of HSP70 were
observed in any of the cell lines studied (data not shown). The secreted
danger signal, HMGB1, was evident in the culture medium of CVA21
and combination-treated bladder cancer cells at 48 and 72hrpost-treat-
ment (Figure 5B); however, no speciﬁc upregulation of extracellular
ATP in response to CVA21 infection could be detected. Of note, infec-
tion with heat-inactivated virus did not induce upregulation of the ICD
markers calreticulin or HMGB1, indicating the need for a productive
CVA21 infection to facilitate immunogenic cell death (Figure S1B).
Figure 5. Selective Induction of HMGB1 and
Calreticulin by CVA21 Infection of Bladder Cancer
Cells
The bladder cancer cell lines, T24, TCCSUP, and 5637,
were either left untreated or treated with Mitomycin-C
(0.5 mg/mL), CVA21, or the combination. Cells and su-
pernatants were harvested at 24, 48, and 72 hr time
points. Cell surface calreticulin (CRT) exposure was
determined by FACS analysis of the cells (A) whereas
HMGB1 accumulation was determined by ELISA analysis
of supernatants (B). Graphs represent pooled data from
two independent experiments, and the statistical signifi-
cance of the treatment group comparisons was analyzed
using two-way ANOVA; *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001.
www.moleculartherapy.orgAs the gold standard approach to evaluate the ability of a speciﬁc
stimulus to cause bona ﬁde ICD relies on vaccination assays,23 a
murine cancer model was developed using the mouse urothelial car-
cinoma cell lineMB49 transfected with human ICAM-1 (Figure S4A).
The susceptibility of the MB49/ICAM-1 cell line to CVA21 was
shown by a signiﬁcant decrease in cell viability compared to the
wild-type MB49 cell line that remained refractile to infection (Fig-
ure S4B). Similar to the human bladder cancer cell lines, MB49/
ICAM-1 cells exposed to the virus released the ICD determinant
HMGB1 (Figure S4C). Thus, C57BL/6 mice were inoculated subcuta-
neously into the ﬂank with lysates generated from MB49/ICAM-1
cells treated with or without CVA21 (Figure 6A). One week later,
viable MB49 cells were introduced into the opposite ﬂank and mice
were monitored for the appearance of palpable neoplastic tumors.
By day 18, 11 days after re-challenge, 100% of the mice that had
initially received lysates from CVA21-treated MB49/ICAM-1 cells
had been effectively vaccinated compared to 50% of the mice that
had initially received untreated MB49/ICAM-1 cell lysates. As ex-
pected, the control mice all developed rapidly growing subcutaneous
tumors.
In order to evaluate which immune cell population(s) were function-
ally important in the protection of the vaccinated mice against re-
challenge with MB49 tumor cells, depletion was conducted one day
prior to initial vaccination using anti-CD8, anti-CD4, or anti-NK
monoclonal antibodies (mAbs). Only the mice depleted of CD4 cellsMolshowed a rapid outgrowth of tumors upon re-
challenge with live MB49 wild-type (WT) cells,
with 82% of the animals succumbing to disease
by the end of the study period. Mice depleted of
CD8+ T cells and natural killer (NK) cells
showed comparable antitumor protection to
immunoglobulin (Ig) control-treated mice,
indicating that these cells do not play an impor-
tant role in the therapeutic effect (Figure 6B). As
expected, the control mice that had been vacci-
nated with only the MB49 cell lysate showed
signiﬁcant tumor outgrowth compared to theisotype control, CD8-, and NK-depleted groups. Collectively, these
data showed for the ﬁrst time an important role for CD4 cells in
the therapeutic response mediated by vaccination with CVA21
MB49/ICAM-1 lysates.
DISCUSSION
Treatment options and their outcomes in NMIBC have not changed
signiﬁcantly in decades.Whereas BCG continues to be the standard of
care in patients with high-grade superﬁcial disease, this is at a signif-
icant cost in terms of morbidity associated with BCG, the frequency
and duration of treatments, and propensity to recur. NMIBC has
been the focus of previous studies using an intravesical route of
administration for a number of non-replicating viruses and OVs
and reviewed recently.24 We have previously shown, using an in vivo
orthotopic bladder tumor model, that the use of an oncolytic herpes-
simplex virus-1 (Oncovex(GALV/CD)) resulted in enhanced local
tumor control by combining oncolysis with the expression of a highly
potent pro-drug activating gene and the fusogenic glycoprotein.25
Other viruses have been evaluated, including reovirus26 and
vaccinia.27 The most advanced studies in humans involve CG0070,
a selectively replicating adenovirus expressing granulocyte macro-
phage colony-stimulating factor (GM-CSF), in which the human
E2F-1 promoter drives expression of the E1A viral gene. CG0070
preferentially replicates in Rb protein-defective bladder cancer cells,
resulting in production of GM-CSF that activates the host immune
response.28 The initial study focused on CIS, Ta, and T1 patientsecular Therapy: Oncolytics Vol. 9 June 2018 7
Figure 6. CVA21-Induced ICD Effectively Vaccinates
Mice
(A) MB49 cells transfected with human ICAM-1 were
treated with or without CVA21 for 24 hr, washed, and
lysates prepared. These lysates along with HANKS media
as a control were injected subcutaneously into one flank of
immunocompetent syngeneic C57BL/6 mice (8 per
group). One week later, mice were re-challenged with
living MB49 cells, which were inoculated subcutaneously
(s.c.) into the contralateral flank. Tumor incidence and
growth were routinely monitored. Graphs represent
pooled data from two independent experiments, and the
means ± SDs of 8 mice per group are shown. Two-way
ANOVA statistical analysis was performed. *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001. (B) Depletion of
CD8+, CD4+, and NK cells in C57BL/6 mice vaccinated
with MB49/ICAM-1 lysates is shown. Depletions were
conducted by intraperitoneal injections of purified mAbs
1 day before re-challenge with viable MB49 cells as well as
throughout the duration of the experiment. Control mice
had been vaccinated with wild-type MB49 cell lysate
before re-challenge with viable MB49 cells and received
no immune-cell-depleting antibodies. Tumor incidence
and growth were monitored, and the statistical signifi-
cance of the intergroup comparisons of tumor volumes
was analyzed using two-way ANOVA. *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001.
Molecular Therapy: Oncolyticswith recurrent NMIBC cancer after BCG treatment and led to the cur-
rent ongoing phase 3 trial for high-grade NMIBC patients who failed
BCG therapy and refused cystectomy.29
Following the success of immune checkpoint inhibition in advanced
bladder cancer, there are numerous trials evaluating the role of anti-
PD-1 agents in NMIBC. Given the limited effect in advanced disease
(25% response rate; median duration 12 months; recently reviewed)30
and the potential toxicities of this form of immunotherapy in an older
population, there is still an urgent need for improved, less toxic local
agents for long-term tumor control. This study demonstrates the
potential of CVA21 as a new oncolytic immunotherapy agent whose
anti-cancer activity can now be extended as a novel treatment
approach to NMIBC. Whereas the majority of bladder cancer cell
lines studied were susceptible to direct oncolysis by CVA21, we
hypothesized that increasing the expression of the viral receptor,
ICAM-1, would further enhance this oncolysis. Treatment of bladder
cancer cell lines with Mitomycin-C, a commonly used chemothera-
peutic agent for bladder cancer, upregulated surface expression of
ICAM-1, resulting in increased viral replication and oncolysis. This
was further demonstrated using precision-cut slices (organotypic
cultures) from a squamous bladder carcinoma case. Culture of these
slices with Mitomycin-C, CVA21, or the combination showed an in-
crease in viral infectivity in the combination-treated slices, and this8 Molecular Therapy: Oncolytics Vol. 9 June 2018also correlated with an increase in apoptosis
within these slices compared to the virus or
Mitomycin-C-treated alone slices. This facilita-tion of virus infection is important in the in vivo setting to ensure a
sufﬁcient amount and concentration of virus such that a robust onco-
lytic effect is initiated.
The direct cytotoxic effect of oncolytic viruses is important, but it is
now well recognized that the anticancer effects of oncolytic viruses
also come from the activation of innate and adaptive tumor-speciﬁc
immunity31–34 and the immunogenicity of dying or dead cancer
cells.11,14 Understanding the mode of cancer cell death induced by
particular oncolytic viruses is important when considering these
agents for cancer therapy. This study revealed that apoptosis was
the primary death pathway induced by CVA21 in bladder cancer
cell lines, as evidenced by annexinV-7AAD staining, activation of
the effector caspases, caspase-3 and -7, and induction of cleaved
PARP. To determine whether this CVA21-induced cell death was
in fact immunogenic, the in vitro characteristics of ICD in bladder
cancer cell lines were investigated. Three damage-associated molecu-
lar patterns (DAMPs) have been attributed a crucial role in the immu-
nogenic potential of nearly all ICD inducers, the surface-exposed
“eat me” signal calreticulin, the “ﬁnd me” signal ATP, and passively
released HMGB111,22 CVA21 infection, induced ecto-calreticulin
and release of HMGB1; however, no speciﬁc secreted ATP could be
detected. The importance of HMGB1 release for initiating an anti-
tumor response in bladder cancer has previously been demonstrated
www.moleculartherapy.orgin the context of BCG. In vivo animal models have shown that tumor
cells engineered to have decreased HMGB1 release fail to respond to
intravesical BCG, thus demonstrating the requirement of HMGB1
release by urothelial carcinoma cells for an in vivo antitumor effect.35
It is thought that HMGB1 signals through its principal receptor,
RAGE, to alter the biology of bladder cancer cells as well as func-
tioning to direct a host cellular immune response to the site of its
release.36
In addition to the molecular DAMP signature, vaccination studies
performed in this study showed the ability to reject MB49 tumors
in syngeneic mice after vaccination with lysates from MB49/
ICAM-1 cells undergoing CVA21-induced ICD. We found this was
dependent on the activation of CD4+T cells and not on CD8+T cells
or NK cells. This is in contrast to previous studies on reovirus, a dou-
ble-stranded RNA virus whose antitumor efﬁcacy depends upon
activation of dendritic cells to stimulate both NK-cell- and
CD8+T-cell-mediated cytotoxicity.34,37 Although the role of
CD4+Th cells in contributing helper functions that modulate activity
of both antigen-presenting cells and cytotoxic CD8+T cells is well es-
tablished,38 there is growing evidence for CD4+Th cells having more
direct antitumor effects.39–41 Future studies are needed to precisely
deﬁne the role of CD4+Th cells in response to CVA21-treated
MB49/ICAM-1 vaccination.
This in vivo tumor-rejecting capacity induced by dying cancer cells in
the absence of any adjuvant is considered as a prerequisite for an
agent to be termed an ICD inducer.22 Thus, CVA21 can now be added
to the growing list of oncolytic virus strains that have been shown to
induce the molecular requirements of ICD, namely coxsackie B3,42
oncolytic adenovirus,33 and Newcastle disease virus.13 Hence, this
further supports the body of evidence that the therapeutic effective-
ness of oncolytic viruses is in large part due to the ICD they induce
and the subsequent potent antitumor immunity this triggers.
In summary, this study shows, for the ﬁrst time, the susceptibility of
bladder cancer cells to CVA21 and the ability to enhance this oncol-
ysis by modulating the expression of the viral receptor ICAM-1 by
Mitomycin-C treatment. Furthermore, the utility of CVA21 as a
potent immunotherapeutic agent was demonstrated by its potential
to elicit several ICD-related DAMPs. The ﬁndings from this study
have provided the rationale for a phase 1 clinical trial CANON
(CAVATAK in non-muscle invasive bladder cancer; https://
clinicaltrials.gov/ct2/show/NCT02316171).43 The immunogenic
potential of CVA21-induced death may be potentially enhanced by
sequential or co-administration of other agents to increase virus up-
take and oncolysis, as well as combination with immune checkpoint
inhibitors.
MATERIALS AND METHODS
CVA21
The Kuykendall prototype strain of coxsackievirus A21 (CVA21)
was obtained from Viralytics Limited (CAVATAK; Sydney,
Australia). To generate heat-inactivated virus, 1 mL aliquots of virusat 7.5  107 PFU were incubated in a waterbath at 60C for 2 hr. The
absence of infectious virus was conﬁrmed by titrating the heat-inac-
tivated virus on the CVA21-sensitive cell line, SK-MEL-28.
Cell Cultures and Treatments
Bladder-cancer-derived cell lines T24, 5637, TCCSUP, KU19-19,
VM-CUB1, and RT-112 were obtained from ATCC. The 253J,
VM-CUB2, and HCV29 cell lines were from Prof. Knowles (Univer-
sity of Leeds). All cell lines were authenticated by DDC Medical. Cell
lines were checked monthly using MycoAlert PLUS Mycoplasma
Detection Kit (Lonza). HCV29, 5637, KU19-19, and RT-112 cell lines
were grown in RPMI 1640; the TCCSUP, VM-CUB1, and VM-CUB2
in DMEM; 253J in 1:1 DMEM:RPMI; J82 in EMEM; and T24 in
McCoy’s. Media was supplemented with 10% fetal bovine serum,
penicillin/streptomycin, and glutamine.
FACS Analysis
Bladder cancer cell lines were incubated with anti-CD54-PE or
CD55-PE antibodies (BD Biosciences) and analyzed using the
MACSQuantify software on a MACSQuant ﬂow cytometer (Miltenyi
Biotec). The cellular antibody-binding capacity of the cell lines was
determined for anti-CD54 using BD Biosciences QuantiBRITE
system (QuantiBRITE standard beads) as previously described.44
Isolation of ICAM-1-Positive Bladder Cancer Cells
KU19-19 cells were labeled with anti-CD54(ICAM-1)-PE (BD Biosci-
ences), washed in PBS, and resuspended in cold MACS buffer (PBS,
0.5% FBS, and 2 mmol EDTA). Superparamagnetic microbeads
conjugated with monoclonal mouse anti-PE antibodies (Miltenyi
Biotec, Germany) were added to the cell pellet and incubated at
4C for 15 min. Cells were washed in cold MACS buffer before being
positively selected on MS+ columns (Miltenyi Biotec).
Immunofluorescence Detection of Infected Cells
Cell lines were seeded into chamber slides (Corning, USA) and left
untreated or infected with CVA21 at the relevant MOI. After 24 hr
in culture, cells were ﬁxed using 4% paraformaldehyde. Fixed cells
were incubated with rhodamine-labeled wheat germ agglutinin
(Molecular Probes), washed, and permeabilized with 0.2%Triton
X-100. After blocking with 10% normal goat serum, cells were stained
with a mouse anti-enterovirus antibody (Clone 5-D8/1; Dako) and
stained for a further 30 min with goat-anti-mouse IgG2a Alexa 488.
Nuclei were stained with TO-PRO-3 (Molecular Probes). Slides
were mounted with Vectashield (Vector Laboratories) and examined
on a Carl Zeiss LSM 510 confocal microscope.
Cell Viability and Cell Death Assays
Cells were infected with CVA21 MOIs at IC50, which for T24 was
11.4, 1.0 for TCCSUP, and 1.8 for 5637. Cell viability was determined
72 hr post-infection by MTS assay (Promega), and the IC50 value was
calculated using CalcuSyn software (Biosoft, UK).
Apoptotic cell death was determined with the annexin V-PE kit
(BD Biosciences). FACS analysis was performed as above.Molecular Therapy: Oncolytics Vol. 9 June 2018 9
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activity post-CVA21 infection. T24, TCCSUP, and 5637 cells were
plated in 96-well plates and incubated overnight. Cells were treated
with 0.5 mg/mL Mitomycin-C and CVA21 as above. At 24, 48, and
72 hr post-treatment, Caspase Glo reagent was used as per manufac-
turer instructions and luminescence measured using a Varioskan
Flash (Thermo Scientiﬁc) plate reader.
To conﬁrm the death pathways involved, the pan-caspase inhibitor
zVAD and the inhibitor of necroptosis, Necrostatin-1 (Sigma-
Aldrich), were used. Necrostatin-1 (30 mM) was added 45 min prior
to Mitomycin-C and/or virus addition, whereas the zVAD (20 mM)
was added after Mitomycin-C and/or virus treatment. Cell viability
was measured using MTS assay (Promega).
In addition, whole-cell lysates were prepared, followed by immuno-
blotting with anti-human PARP (no. 9542; Cell Signaling Technol-
ogy, USA), anti-RIP1 (BD Biosciences), and anti-RIP-3 (Abcam)
antibodies.
Viral Proliferation Assays
Viral proliferation assays were performed to assess ICAM-1-induced
upregulation by Mitomycin-C on viral replication. Cells were grown
in 6-well plates and treated with/without 0.5 mg/mLMitomycin-C for
1 hr before infecting with CVA21 at the relevant MOI for each line.
Cells were exposed to CVA21 for 5 hr before washing and media
replenishment. Supernatants were harvested 24, 48, and 72 hr
post-infection and dilutions made from 101 to 1014. To determine
the virus production, replication assays were performed using
SK-MEL-28 cells. The CVA21 virus titer (TCID50/mL) was calcu-
lated using Spearman and Karber algorithm.
ICD Determinant Analysis
FACS analysis was used to determine expression of ICD determinants
on the surfaces of treated cells. Cell lines untreated, treated withMito-
mycin-C (0.5 mg/mL) for 1 hr, or exposed to CVA21 for 24–72 hr with
or without prior Mitomycin-C treatment were harvested and incu-
bated with anti-HSP70, anti-calreticulin, and an isotype control
(Abcam). Additional stains included MHCII (BioLegend), CD80
(eBioscience), FAS (Abcam), and PD-L1 (eBioscience). Relevant
secondary Alexa-488-labeled antibodies were subsequently applied
(Molecular Probes).
Released HMGB1 was measured in the conditionedmedia of cell lines
by ELISA (IBL International, Hamburg, Germany) and extracellular
ATP by ATP determination kit (Molecular Probes).
Vaccination Assay for the Evaluation of ICD In Vivo
In vivo procedures were approved by the UK Home Ofﬁce and by
AWERB of the University of Surrey. MB49 cells transfected with
human ICAM-1 were treated with or without CVA21 (IC50 6.25)
for 24 hr, washed, and lysates prepared. Lysates, along with HANKS
media as a control, were injected subcutaneously into one ﬂank of
immunocompetent syngeneic female C57BL/6 JOlaHsd mice10 Molecular Therapy: Oncolytics Vol. 9 June 2018(42–49 days; Envigo). One week later, mice were re-challenged with
live 1e6 MB49 cells subcutaneously into the contralateral ﬂank.
Immunodepletion studies were conducted with mAbs anti-CD4
(GK1.5), anti-CD8a (clone 2.43), anti-NK1.1 (clone PK136), and
mouse IgG2a (clone C1.18.4) and rat IgG2b (clone LTF-2) isotype
controls (Bio X Cell). Puriﬁed mAbs (100 mg) were injected intraper-
itoneally twice weekly starting one day before re-challenge with live
1e6 MB49 cells. The efﬁciency of depletion of lymphocyte subsets
was measured by ﬂow cytometry.
Bladder Tumor Precision-Cut Slice Preparation and Treatment
Tissue was obtained from consenting patients during a transurethral
bladder tumor removal at the Royal Surrey County Hospital, Guild-
ford, UK and transported to the laboratory for slicing within 1 hr.
Ethics approval was given by London-Brent Research Ethics Commit-
tee study no. 12/LO/1661. Tumor tissue of small volume was
embedded in 4% agarose. 300-mm slices were prepared using the
vibrating blade microtome (Leica VT1200S). Bladder tumor slices
were subsequently cultured in DMEM supplemented as above. Slices
were either left untreated, treated with Mitomycin-C (0.5 mg/mL) for
1 hr before removing the drug, or exposed to CVA21 (5 106) with or
without prior treatment with Mitomycin-C. Cultivation was per-
formed at 37C and 5% CO2 for 48 hr. Slices were harvested and ﬁxed
in 10% neutral-buffered formalin (Sigma Aldrich) before embedding
in parafﬁn.
Immunohistochemistry
4-mm parafﬁn sections were stained with H&E. Immunohistochem-
istry (IHC) staining was carried out to detect apoptosis using the
TumorTACS In Situ Apoptosis Detection kit (Trevigen). DNA frag-
mentation in the tumor tissues was visualized using 3,30-diaminoben-
zidine (DAB) chromogen and counterstained with 1% Methyl Green.
Sections were then dehydrated and mounted.
To detect viral protein within tumor slices, 4-mm parafﬁn sections
were dewaxed and rehydrated before being subjected to heat-medi-
ated antigen retrieval in a microwave using citrate buffer (10 mM;
pH 6.0). Sections were incubated with an anti-enterovirus antibody
(clone 5-D8/1; Dako) followed by a goat anti-mouse IgG2a-Alexa
488 and TO-PRO-3 (Molecular Probes) before mounting using
Vectashield (Vector Labs). Replacement of the primary antibody by
PBS/BSA 1% was used as a negative control. Results were analyzed
by confocal microscopy using a LSM 510 Carl Zeiss confocal
microscope.
Statistical Analysis
The GraphPad Prism software package was used to construct graphs
and for statistical calculations. Each experiment was performed twice.
Two-way ANOVA with Bonferroni correction was used in all in vitro
bladder cancer cell line experiments comparing different treatment
groups (untreated, Mitomycin C, CVA21, and the combination).
Data comparing multiple animal groups in in vivo studies were also
analyzed by two-way ANOVA. The one-way ANOVA with
www.moleculartherapy.orgBonferroni correction was performed for analysis of IFNb ELISA
results. Results are shown as (±) SE bars obtained from the means
of each group. The following symbols were used in diagrams/ﬁgures
to denote levels of signiﬁcance: *p < 0.05; **p < 0.01; ***p < 0.001; and
****p < 0.0001.
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